Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Beijing QL Biopharmaceutical Co.,Ltd
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07550816CT.gov Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | — | Not Yet Recruiting | — | — | — |
NCT07269756CT.gov A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects | — | Completed | — | — | — |
NCT06982131CT.gov A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | — | Recruiting | — | — | — |
NCT06601517CT.gov A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. | — | Not Yet Recruiting | — | — | — |
NCT06567327CT.gov A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese | — | Completed | — | — | — |
NCT06279234CT.gov A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus | — | Completed | — | — | — |
NCT06186622CT.gov A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants | — | Completed | — | — | — |
NCT06247748CT.gov Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects | — | Completed | — | — | — |
NCT04621227CT.gov Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity | — | Completed | — | — | — |
NCT00485121CT.gov Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rosuvastatin (this asset) | Beijing QL Biopharmaceutical Co.,Ltd | P1 | CCC · 51 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Rosuvastatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Inherited Lipid Metabolism Disorder | — | P4 | A · 81 |
| Hyperlipidemia | — | P4 | BBB · 77 |
| Cardiovascular Disorder | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rosuvastatin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rosuvastatin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →